Oğuz Abdullah Uyaroğlu, Meliha Çağla Sönmezer, Gülçin Telli Dizman, Nursel Çalık Başaran, Sevilay Karahan, Ömrüm Uzun

Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Single- center, Retrospective, Propensity Score-matched Study

Objectives: In this study, we compared the clinical outcomes and effects of the treatments on laboratory parameters between patients who were treated with favipiravir (FAV) or hydroxychloroquine plus azithromycin (HCQ/AZ) for COVID-19 pneumonia in non-Intensive Care Unit (non-ICU) patients. Methods: We collected data of 260 moderate or severe COVID-19 patients hospitalized in COVID-19 wards between March 20, 2020, and September 30, 2020 retrospectively. We used propensity score matching to evaluate treatment effect on laboratory parameters of COVID-19 infection. Results: We compared 42 patients using FAV and 42 HCQ/AZ after propensity score matching. While there were statistical differences between the therapy groups in terms of transfer to ICU and/or exitus before matching (p=0.031), this was not significant after propensity analysis (p=0.250). Patients treated with FAV stayed in the hospital nearly one more day than HCQ/AZ group but the difference was not statistically significant (9.02 days vs 8.14 days, p=0.903). The levels of AST,ALT, and LDH increased at discharge in both groups, especially in the FAV group. Conclusions: FAV is not superior to HCQ/AZ in the treatment of COVID-19 infection in hospitalized patients with pneumonia.

PDF

___

1] World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int
[2] World Health Organization (WHO). New updates. Latest news from WHO on COVID-19 and other breaking health stories. Updated on 21 January 2021. Available from: https://www.who.int/news-room/news-updates
[3] World Health Organization (WHO). Therapeutics and COVID-19: living guideline. Updated on 31 March 2021.
[4] Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020;56(1):105949.
[5] Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. bmj. 2020;369.
[6] Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquineinhospitalizedpatientswithCovid-19. New England Journal of Medicine. 2020;382(25):2411-8.
[7] Piszczatoski, Christopher R., and Jason Powell.“Emergency authorization of chloroquine and hydroxychloroquine for treatment of COVID-19.” Annals of Pharmacotherapy 54.8 (2020): 827-831.
[8] World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/global-research-on- novel-coronavirus-2019-ncov/solidarity-clinical-trial-for- covid-19-treatments.
[9] RECOVERY Collaborative Group. “Effect of hydroxychloroquine in hospitalized patients with Covid-19.”New England Journal of Medicine 383.21 (2020): 2030-2040.
[10] Simmering JE, Polgreen LA, Polgreen PM, Teske RE, Comellas AP, Carter BL. The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. Pharmacotherapy. 2020;40(9):978-983. doi:10.1002/ phar.2445
[11] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020;30(3):269-71.
[12] Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases. 2020.
[13] Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research 2013;100(2):446-54.
14] Bouazza N, Treluyer J-M, Foissac F, et al. Favipiravir for children with Ebola. Lancet 2015;385(9968):603-4.
[15] Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 2020;6(10):1192-8.
[16] Yamamura H, Matsuura H, Nakagawa J, et al. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Critical Care 2020;24(1):413.
[17] Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a pha se II/III multicenter randomized clinical trial. Clinical Infectious Disease 2020 Aug 9:ciaa1176.
[18] Fu D, Cao R, Zhao L, et al. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series. Crital Care 2020;24(1):578.
[19] Doi K, Ikeda M, Hayase N, et al. Nafa mostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crital Care 2020;24(1):392.
[20] Doi Y, Hibino M, Hase R, et al. “A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19.” Antimicrobial agents and chemotherapy 64.12 (2020).
[21] Kocayiğit H, Özmen Süner K, Tomak Y, et al. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19. Journal of Clinical Pharmacy and Therapeutics 2020 Oct 31.
[22] Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 patients: An exploratory randomized, controlled trial. European Journal of Pharmaceutical Sciences 2020:105631.
[23] Republic of Turkey Ministry of Health Directorate General of Public Health (2020). COVID-19 (SARS-CoV-2 Infection) Guide (in Turkish). Available from: https://covid19.saglik. gov.tr/Eklenti/39061/0/covid-19rehberieriskinhastatedav isipdf.pdf
[24] World Health Organization (WHO). COVID-19 Clinical management: living guidance. Updated on 11 January 2021.
[25] Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv (2020).
[26] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020;19:149-50.
[27] Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Archives of Virology 2021;166(3):949- 954.
[28] Dabbous HM, El-Sayed MH, El Assal G, et al. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Scientific Reports. 2021;11(1):7282.
[29] Özlüşen B, Kozan Ş, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40(12):2575-2583.
[30] Victoria P, Pepperrell T, Hill A. A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?. Journal of virus eradication 2020; 6 (2): 45-51.
[31] Çalık Başaran N, Uyaroğlu OA, Telli Dizman G, et al. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turk J Med Sci. 2021: 30;51(2): 411-420.
[32] Inkaya AÇ, Kara E, Çalik Başaran N, et al. Pretreatment serum uric acid level is not a surrogate marker for the outcome of favipiravir treatment in COVID-19 patients. Turk J Med Sci. 2021;51: 2786-2788.
[33] Yuki H, Sadako Y, Kazuhiro M, et al. Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir. Diagn. Microbiol. Infect. Dis. 2022; 115640.
[34] Çilingir BM, Sunnetcioglu A, Yildiz H, et al. What Is The Case of More Accessible Treatment Options in COVID 19: Comparison of Hydroxychloroquine and Favipiravir Based on Laboratory Values. Eastern Journal of Medicine, 2021; 26(3): 426-432.